title: Screening for tuberculosis infection among newly arrived asylum seekers: comparison of QuantiFERONTB Gold with tuberculin skin test.
abstract: BACKGROUND
  QuantiFERONTB Gold (QFT) is a promising blood test for tuberculosis infection but with few data so far from immigrant screening. The aim of this study was to compare results of QFT and tuberculin skin test (TST) among newly arrived asylum seekers in Norway and to assess the role of QFT in routine diagnostic screening for latent tuberculosis infection.
  
  
  METHODS
  The 1000 asylum seekers (age > or = 18 years) enrolled in the study were voluntarily recruited from 2813 consecutive asylum seekers arriving at the national reception centre from September 2005 to June 2006. Participation included a QFT test and a questionnaire in addition to the mandatory TST and chest X-ray.
  
  
  RESULTS
  Among 912 asylum seekers with valid test results, 29% (264) had a positive QFT test whereas 50% (460) tested positive with TST (indurations > or = 6 mm), indicating a high proportion of latent infection within this group. Among the TST positive participants 50% were QFT negative, whereas 7% of the TST negative participants were QFT positive. There was a significant association between increase in size of TST result and the likelihood of being QFT positive. Agreement between the tests was 71-79% depending on the chosen TST cut-off and it was higher for non-vaccinated individuals.
  
  
  CONCLUSIONS
  By using QFT in routine screening, further follow-up could be avoided in 43% of the asylum seekers who would have been referred if based only on a positive TST (> or = 6 mm). The proportion of individuals referred will be the same whether QFT replaces TST or is used as a supplement to confirm a positive TST, but the number tested will vary greatly. All three screening approaches would identify the same proportion (88-89%) of asylum seekers with a positive QFT and/or a TST > or = 15 mm, but different groups will be missed.
authors.affiliation: Division of Infectious Disease Epidemiology, Norwegian Institute of Public Health, 0403 Oslo, Norway. brita.winje@fhi.no
authors.forename: Brita Askeland
authors.initials: BA
authors.lastname: Winje
authors.forename: Fredrik
authors.initials: F
authors.lastname: Oftung
authors.forename: Gro Ellen
authors.initials: GE
authors.lastname: Korsvold
authors.forename: Turid
authors.initials: T
authors.lastname: Mannsåker
authors.forename: Anette Skistad
authors.initials: AS
authors.lastname: Jeppesen
authors.forename: Ingunn
authors.initials: I
authors.lastname: Harstad
authors.forename: Berit Tafjord
authors.initials: BT
authors.lastname: Heier
authors.forename: Einar
authors.initials: E
authors.lastname: Heldal
mesh_terms: D000293:Adolescent; D000328:Adult; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000276:immunology; D009664:Norway; D011933:Reagent Kits, Diagnostic; D012036:Refugees; D014374:Tuberculin Test; D014376:Tuberculosis / Q000097:blood / Q000175:diagnosis*
chemical_list: D011933:Reagent Kits, Diagnostic; D007371:Interferon-gamma